T1	intervention 0 10	Exemestane
T2	total-participants 131 136	4,560
T3	eligibility 137 167	high-risk postmenopausal women
T4	iv-bin-percent 177 180	65%
T5	outcome 181 216	reduction in invasive breast cancer
T6	outcome 294 308	adverse events
